Abstract | OBJECTIVE: PATIENTS AND METHODS: RESULTS: In all, 284 men received either triptorelin (140) or leuprolide (144). The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%). The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups. Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033). Both treatments were well tolerated. CONCLUSION:
|
Authors | C F Heyns, M-P Simonin, P Grosgurin, R Schall, H C Porchet, South African Triptorelin Study Group |
Journal | BJU international
(BJU Int)
Vol. 92
Issue 3
Pg. 226-31
(Aug 2003)
ISSN: 1464-4096 [Print] England |
PMID | 12887472
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Antineoplastic Agents, Hormonal
- Triptorelin Pamoate
- Gonadotropin-Releasing Hormone
- Testosterone
- Leuprolide
|
Topics |
- Aged
- Aged, 80 and over
- Analgesics
(therapeutic use)
- Antineoplastic Agents, Hormonal
(administration & dosage, adverse effects)
- Castration
(methods)
- Gonadotropin-Releasing Hormone
(agonists)
- Humans
- Leuprolide
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Prostatic Neoplasms
(blood, drug therapy)
- Survival Analysis
- Testosterone
(blood)
- Treatment Outcome
- Triptorelin Pamoate
(administration & dosage, adverse effects, analogs & derivatives)
|